Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AE58054 as Augmentation to Risperidone in Schizophrenia
NCT00810667Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Nov 2008
- Primary completion
- Jan 2010
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Lu AE58054 + Risperidone with Placebo + Risperidone (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Nov 2008; status: completed.
02
Drugs
Idalopirdine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00810667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810667.